'Rigged' pay­ment schemes by in­sur­ers and PBMs is block­ing the switch to biosim­i­lars, says FDA com­mis­sion­er

Hav­ing called out brand name drug com­pa­nies for de­lay­ing mar­ket en­try of gener­ic drugs, FDA Com­mis­sion­er Scott Got­tlieb made in­sur­ers and phar­ma­cy ben­e­fit …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER